メラノーマ治療薬市場：タイプ、製品、流通チャネル別-2025-2030年の世界予測

メラノーマ治療薬市場は、2023年に54億米ドルと評価され、2024年には58億1,000万米ドルに達すると予測され、CAGR 8.32％で成長し、2030年には94億5,000万米ドルに達すると予測されています。

メラノーマ治療薬市場には、主にメラニン産生細胞から発生する重篤な皮膚がんであるメラノーマの発見、予防、治療に使用される一連の治療法が含まれます。メラノーマ治療薬の必要性は、長時間の紫外線曝露や遺伝的素因などの要因によって増加する世界のメラノーマ発生率に起因しており、それによって効果的な治療が必要とされています。その用途は個別化医療、免疫療法、標的療法、化学療法に及び、病院、診療所、がん研究機関、専門医療センターなどの1次エンドユーザーにサービスを提供しています。主な成長要因としては、バイオテクノロジーの進歩、研究開発投資の増加、がんの早期発見を促進する政府の取り組み、革新的な薬剤の需要を高めるメラノーマの有病率の上昇などが挙げられます。最新のビジネスチャンスは、個別化免疫療法や、耐性に対処し既存治療の有効性を向上させる併用療法の開発にあります。こうした機会を捉えるには、最先端研究への投資、バイオテクノロジー企業との提携、創薬におけるAIの活用が成長の原動力となります。しかし、治療費の高さ、規制要件の厳しさ、副作用の可能性などが課題となっており、採用が制限されています。また、ジェネリック医薬品との競合や、明確な治療アプローチを必要とする早期診断という課題も市場成長の制約となっています。この市場の開拓は、副作用の少ない薬剤の開発、CRISPR遺伝子編集技術の活用、多様な患者プロファイルに対応する包括的な多剤併用レジメンの創出を軸に進められると思われます。調査では、ナノテクノロジーとバイオ医薬品の融合をさらに追求することができます。市場力学はもともとダイナミックなものであり、科学の進歩と効果的な解決策への緊急なニーズの両方によって推進され、固有の課題と規制状況を戦略的にナビゲートする必要がある一方で、成長のための数多くの道を提示しています。

市場力学：急速に進化するメラノーマ治療薬市場の主要市場インサイトを公開

メラノーマ治療薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響についてより明確に理解することができます。

• 市場促進要因
  • メラノーマおよびその他の皮膚がんの世界の有病率の上昇
  • ヘルスケアに対する政府支出の増加
  • がん領域におけるバイオシミラー開発の活発化
• 市場抑制要因
  • 薬剤開発と治療に伴う高コスト
• 市場機会
  • 副作用の軽減と高い効率性による標的治療へのニーズの高まり
  • 効果的な薬剤を導入するための継続的な研究開発活動
• 市場の課題
  • 厳しい規制政策と長い承認プロセス

ポーターのファイブフォース：メラノーマ治療薬市場をナビゲートする戦略ツール

ポーターのファイブフォース」フレームワークは、市場情勢の競合情勢を把握するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することで、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：メラノーマ治療薬市場における外部からの影響の把握

外部マクロ環境要因は、メラノーマ治療薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析メラノーマ治療薬市場における競合情勢の把握

メラノーマ治療薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスメラノーマ治療薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、メラノーマ治療薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨メラノーマ治療薬市場における成功への道筋を描く

メラノーマ治療薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で黒色腫やその他の皮膚がんの罹患率が上昇
    • ヘルスケアに対する政府支出の増加
    • 腫瘍学分野におけるバイオシミラーの開発促進
  • 抑制要因
    • 医薬品の開発と治療にかかる高額な費用
  • 機会
    • 副作用の減少と効率性の向上による標的治療の必要性の高まり
    • 有効な薬剤の導入に向けた研究開発活動を継続
  • 課題
    • 厳格な規制方針と長い承認プロセス
• 市場セグメンテーション分析
  • タイプ：末端黒子型悪性黒色腫および黒子型悪性黒色腫における非侵襲的治療法の需要の高まり
  • 製品：悪性黒色腫の病気の進行と遺伝子変異を治療する次世代医薬品の需要が増加
  • 流通チャネル：利便性と遠隔医療サポートによるオンラインチャネルの需要の高まり
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 メラノーマ治療薬市場：タイプ別

• 末端黒子型黒色腫
• 悪性黒子
• 結節性黒色腫
• 表面拡散型黒色腫

第7章 メラノーマ治療薬市場：製品別

• 補助療法
• 生物化学療法
• 化学療法薬
  • ダカルバジン（DTIC-ドーム）
  • テモゾロミド（テモダール）
• 免疫療法薬
  • チェックポイント阻害剤
  • CTLA-4阻害剤
• 腫瘍溶解性ウイルス療法
• 標的治療薬
  • BRAF阻害剤
  • MEK阻害剤

第8章 メラノーマ治療薬市場：流通チャネル別

• オフライン
  • 病院薬局
  • 小売薬局
• オンライン

第9章 南北アメリカのメラノーマ治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域のメラノーマ治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカのメラノーマ治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • モデナ社とメルク社は、mRNA-4157（V940）とキイトルーダ（R）（ペンブロリズマブ）の併用により、高リスクステージIII/IV悪性黒色腫患者の完全切除後3年時点でのキイトルーダ投与と比較して無再発生存率と無遠隔転移生存率の継続的な改善が実証されたと発表しました。
  • サンファーマとフィロジェンのメラノーマ治療薬が第3相試験で有望な結果を示す
  • 米国食品医薬品局、ステージIIBまたはステージIICの悪性黒色腫の完全切除を受けた適格患者に対する補助治療としてオプジーボ（ニボルマブ）を承認
• 戦略分析と提言

企業一覧

• AB Science
• AbbVie Inc.
• Amgen Inc.
• AstraZeneca PLC
• Bristol-Myers Squibb Company
• CK Life Sciences Int'l.,（Holdings）Inc.
• Clinigen Group PLC
• Eli Lilly and Company
• Enzon Pharmaceuticals, Inc.
• F. Hoffmann-La Roche Ltd.
• Genentech, Inc.
• GlaxoSmithKline PLC
• Hikma Pharmaceuticals PLC
• Immunocore Limited
• Merck KGaA
• Moderna, Inc
• Novartis AG
• Pfizer, Inc.
• Philogen S.p.A.
• Regeneron Pharmaceuticals Inc.
• Sun Pharmaceutical Industries Limited
• Taj Pharmaceuticals Limited
• Takeda Pharmaceutical Company Limited
• Wellona Pharma

LIST OF FIGURES

• FIGURE 1. MELANOMA DRUG MARKET RESEARCH PROCESS
• FIGURE 2. MELANOMA DRUG MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL MELANOMA DRUG MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL MELANOMA DRUG MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL MELANOMA DRUG MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL MELANOMA DRUG MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES MELANOMA DRUG MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES MELANOMA DRUG MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. MELANOMA DRUG MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. MELANOMA DRUG MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. MELANOMA DRUG MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL MELANOMA DRUG MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL MELANOMA DRUG MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. MELANOMA DRUG MARKET DYNAMICS
• TABLE 7. GLOBAL MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL MELANOMA DRUG MARKET SIZE, BY ACRAL LENTIGINOUS MELANOMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL MELANOMA DRUG MARKET SIZE, BY LENTIGO MALIGNA MELANOMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL MELANOMA DRUG MARKET SIZE, BY NODULAR MELANOMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL MELANOMA DRUG MARKET SIZE, BY SUPERFICIAL SPREADING MELANOMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL MELANOMA DRUG MARKET SIZE, BY ADJUVANT THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL MELANOMA DRUG MARKET SIZE, BY BIOCHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL MELANOMA DRUG MARKET SIZE, BY DACARBAZINE (DTIC-DOME), BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL MELANOMA DRUG MARKET SIZE, BY TEMOZOLOMIDE (TEMODAR), BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL MELANOMA DRUG MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL MELANOMA DRUG MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL MELANOMA DRUG MARKET SIZE, BY BRAF INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL MELANOMA DRUG MARKET SIZE, BY MEK INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL MELANOMA DRUG MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL MELANOMA DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL MELANOMA DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL MELANOMA DRUG MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. AMERICAS MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 35. AMERICAS MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 36. AMERICAS MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 37. AMERICAS MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 38. AMERICAS MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 39. AMERICAS MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 40. AMERICAS MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 41. AMERICAS MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 42. ARGENTINA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 43. ARGENTINA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 44. ARGENTINA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 45. ARGENTINA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 46. ARGENTINA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 47. ARGENTINA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 48. ARGENTINA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 49. BRAZIL MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 50. BRAZIL MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 51. BRAZIL MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 52. BRAZIL MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 53. BRAZIL MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 54. BRAZIL MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 55. BRAZIL MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 56. CANADA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 57. CANADA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 58. CANADA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 59. CANADA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 60. CANADA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 61. CANADA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 62. CANADA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 63. MEXICO MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 64. MEXICO MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 65. MEXICO MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 66. MEXICO MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 67. MEXICO MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 68. MEXICO MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 69. MEXICO MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 70. UNITED STATES MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 71. UNITED STATES MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 72. UNITED STATES MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 73. UNITED STATES MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 74. UNITED STATES MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 75. UNITED STATES MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 76. UNITED STATES MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 77. UNITED STATES MELANOMA DRUG MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 78. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 79. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 80. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 81. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 82. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 83. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 84. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 85. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 86. AUSTRALIA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 87. AUSTRALIA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 88. AUSTRALIA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 89. AUSTRALIA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 90. AUSTRALIA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 91. AUSTRALIA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 92. AUSTRALIA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 93. CHINA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 94. CHINA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 95. CHINA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 96. CHINA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 97. CHINA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 98. CHINA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 99. CHINA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 100. INDIA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 101. INDIA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 102. INDIA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 103. INDIA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 104. INDIA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 105. INDIA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 106. INDIA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 107. INDONESIA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 108. INDONESIA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 109. INDONESIA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 110. INDONESIA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 111. INDONESIA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 112. INDONESIA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 113. INDONESIA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 114. JAPAN MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 115. JAPAN MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 116. JAPAN MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 117. JAPAN MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 118. JAPAN MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 119. JAPAN MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 120. JAPAN MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 121. MALAYSIA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 122. MALAYSIA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 123. MALAYSIA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 124. MALAYSIA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 125. MALAYSIA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 126. MALAYSIA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 127. MALAYSIA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 128. PHILIPPINES MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 129. PHILIPPINES MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 130. PHILIPPINES MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 131. PHILIPPINES MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 132. PHILIPPINES MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 133. PHILIPPINES MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 134. PHILIPPINES MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 135. SINGAPORE MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 136. SINGAPORE MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 137. SINGAPORE MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 138. SINGAPORE MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 139. SINGAPORE MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 140. SINGAPORE MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 141. SINGAPORE MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 142. SOUTH KOREA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 143. SOUTH KOREA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 144. SOUTH KOREA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 145. SOUTH KOREA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 146. SOUTH KOREA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 147. SOUTH KOREA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 148. SOUTH KOREA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 149. TAIWAN MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 150. TAIWAN MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 151. TAIWAN MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 152. TAIWAN MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 153. TAIWAN MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 154. TAIWAN MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 155. TAIWAN MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 156. THAILAND MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 157. THAILAND MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 158. THAILAND MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 159. THAILAND MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 160. THAILAND MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 161. THAILAND MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 162. THAILAND MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 163. VIETNAM MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 164. VIETNAM MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 165. VIETNAM MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 166. VIETNAM MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 167. VIETNAM MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 168. VIETNAM MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 169. VIETNAM MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 170. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 171. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 172. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 173. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 174. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 175. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 176. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 177. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 178. DENMARK MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 179. DENMARK MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 180. DENMARK MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 181. DENMARK MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 182. DENMARK MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 183. DENMARK MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 184. DENMARK MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 185. EGYPT MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 186. EGYPT MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 187. EGYPT MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 188. EGYPT MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 189. EGYPT MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 190. EGYPT MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 191. EGYPT MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 192. FINLAND MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 193. FINLAND MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 194. FINLAND MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 195. FINLAND MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 196. FINLAND MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 197. FINLAND MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 198. FINLAND MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 199. FRANCE MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 200. FRANCE MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 201. FRANCE MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 202. FRANCE MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 203. FRANCE MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 204. FRANCE MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 205. FRANCE MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 206. GERMANY MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 207. GERMANY MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 208. GERMANY MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 209. GERMANY MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 210. GERMANY MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 211. GERMANY MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 212. GERMANY MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 213. ISRAEL MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 214. ISRAEL MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 215. ISRAEL MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 216. ISRAEL MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 217. ISRAEL MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 218. ISRAEL MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 219. ISRAEL MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 220. ITALY MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 221. ITALY MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 222. ITALY MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 223. ITALY MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 224. ITALY MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 225. ITALY MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 226. ITALY MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 227. NETHERLANDS MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 228. NETHERLANDS MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 229. NETHERLANDS MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 230. NETHERLANDS MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 231. NETHERLANDS MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 232. NETHERLANDS MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 233. NETHERLANDS MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 234. NIGERIA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 235. NIGERIA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 236. NIGERIA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 237. NIGERIA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 238. NIGERIA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 239. NIGERIA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 240. NIGERIA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 241. NORWAY MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 242. NORWAY MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 243. NORWAY MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 244. NORWAY MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 245. NORWAY MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 246. NORWAY MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 247. NORWAY MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 248. POLAND MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 249. POLAND MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 250. POLAND MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 251. POLAND MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 252. POLAND MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 253. POLAND MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 254. POLAND MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 255. QATAR MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 256. QATAR MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 257. QATAR MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 258. QATAR MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 259. QATAR MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 260. QATAR MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 261. QATAR MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 262. RUSSIA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 263. RUSSIA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 264. RUSSIA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 265. RUSSIA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 266. RUSSIA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 267. RUSSIA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 268. RUSSIA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 269. SAUDI ARABIA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 270. SAUDI ARABIA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 271. SAUDI ARABIA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 272. SAUDI ARABIA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 273. SAUDI ARABIA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 274. SAUDI ARABIA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 275. SAUDI ARABIA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 276. SOUTH AFRICA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 277. SOUTH AFRICA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 278. SOUTH AFRICA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 279. SOUTH AFRICA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 280. SOUTH AFRICA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 281. SOUTH AFRICA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 282. SOUTH AFRICA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 283. SPAIN MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 284. SPAIN MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 285. SPAIN MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 286. SPAIN MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 287. SPAIN MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 288. SPAIN MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 289. SPAIN MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 290. SWEDEN MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 291. SWEDEN MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 292. SWEDEN MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 293. SWEDEN MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 294. SWEDEN MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 295. SWEDEN MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 296. SWEDEN MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 297. SWITZERLAND MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 298. SWITZERLAND MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 299. SWITZERLAND MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 300. SWITZERLAND MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 301. SWITZERLAND MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 302. SWITZERLAND MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 303. SWITZERLAND MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 304. TURKEY MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 305. TURKEY MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 306. TURKEY MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 307. TURKEY MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 308. TURKEY MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 309. TURKEY MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 310. TURKEY MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 311. UNITED ARAB EMIRATES MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 312. UNITED ARAB EMIRATES MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 313. UNITED ARAB EMIRATES MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 314. UNITED ARAB EMIRATES MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 315. UNITED ARAB EMIRATES MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 316. UNITED ARAB EMIRATES MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 317. UNITED ARAB EMIRATES MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 318. UNITED KINGDOM MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 319. UNITED KINGDOM MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 320. UNITED KINGDOM MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 321. UNITED KINGDOM MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 322. UNITED KINGDOM MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
• TABLE 323. UNITED KINGDOM MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 324. UNITED KINGDOM MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 325. MELANOMA DRUG MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 326. MELANOMA DRUG MARKET, FPNV POSITIONING MATRIX, 2023

The Melanoma Drug Market was valued at USD 5.40 billion in 2023, expected to reach USD 5.81 billion in 2024, and is projected to grow at a CAGR of 8.32%, to USD 9.45 billion by 2030.

The Melanoma Drug market encompasses a range of therapeutic treatments used primarily for the detection, prevention, and therapy of melanoma, a severe form of skin cancer arising from melanin-producing cells. The necessity of melanoma drugs stems from increasing global melanoma incidences, heightened by factors such as prolonged UV exposure, and genetic predisposition, thereby necessitating effective treatments. Applications extend to personalized medicine, immunotherapy, targeted therapy, and chemotherapy, serving primary end-users such as hospitals, clinics, cancer research institutes, and specialty care centers. Key growth influencers include advancements in biotechnology, increased R&D investments, government initiatives promoting early cancer detection, and a rising prevalence of melanoma enhancing the demand for innovative drugs. Latest opportunities lie in the development of personalized immunotherapies and combination therapies that address resistance and improve the efficacy of existing treatments. To seize these opportunities, investing in cutting-edge research, collaborations with biotech firms, and leveraging AI in drug discovery can drive growth. However, challenges include the high cost of treatment, stringent regulatory requirements, and potential side effects limiting adoption. Market growth is also constrained by competition from generic drugs and the challenge of early-stage diagnosis requiring distinct treatment approaches. Innovations in this market could pivot around developing drugs with lower side effects, utilizing CRISPR gene-editing technology, and creating comprehensive multi-drug regimens that cater to diverse patient profiles. Research can further explore the integration of nanotechnology and biopharmaceuticals. The melanoma drug market is dynamic by nature, driven by both scientific progress and an urgent need for effective solutions, presenting numerous avenues for growth while requiring strategic navigation of inherent challenges and regulatory landscapes.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Melanoma Drug Market

The Melanoma Drug Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising prevalence of melanoma and other skin cancers globally
  • Increase in government expenditures on healthcare
  • Elevated development of biosimilar in oncology arena
• Market Restraints
  • High costs associated with drug development and treatment
• Market Opportunities
  • Emerging need for targeted therapy owing to reduced side effects and higher efficiency
  • Ongoing research and development activities to introduce effective drugs
• Market Challenges
  • Stringent regulatory policies and lengthy approval process

Porter's Five Forces: A Strategic Tool for Navigating the Melanoma Drug Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Melanoma Drug Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Melanoma Drug Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Melanoma Drug Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Melanoma Drug Market

A detailed market share analysis in the Melanoma Drug Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Melanoma Drug Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Melanoma Drug Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Melanoma Drug Market

A strategic analysis of the Melanoma Drug Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Melanoma Drug Market, highlighting leading vendors and their innovative profiles. These include AB Science, AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, CK Life Sciences Int'l., (Holdings) Inc., Clinigen Group PLC, Eli Lilly and Company, Enzon Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., Genentech, Inc., GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Immunocore Limited, Merck KGaA, Moderna, Inc, Novartis AG, Pfizer, Inc., Philogen S.p.A., Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Limited, Taj Pharmaceuticals Limited, Takeda Pharmaceutical Company Limited, and Wellona Pharma.

Market Segmentation & Coverage

This research report categorizes the Melanoma Drug Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Acral Lentiginous Melanoma, Lentigo Maligna Melanoma, Nodular Melanoma, and Superficial Spreading Melanoma.
• Based on Product, market is studied across Adjuvant Therapy, Biochemotherapy, Chemotherapy Drugs, Immunotherapy Drugs, Oncolytic Virus Therapy, and Targeted Therapy Drugs. The Chemotherapy Drugs is further studied across Dacarbazine (DTIC-Dome) and Temozolomide (Temodar). The Immunotherapy Drugs is further studied across Checkpoint Inhibitors and CTLA-4 Inhibitors. The Targeted Therapy Drugs is further studied across BRAF Inhibitors and MEK Inhibitors.
• Based on Distribution Channel, market is studied across Offline and Online. The Offline is further studied across Hospital Pharmacies and Retail Pharmacies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of melanoma and other skin cancers globally
    • 5.1.1.2. Increase in government expenditures on healthcare
    • 5.1.1.3. Elevated development of biosimilar in oncology arena
  • 5.1.2. Restraints
    • 5.1.2.1. High costs associated with drug development and treatment
  • 5.1.3. Opportunities
    • 5.1.3.1. Emerging need for targeted therapy owing to reduced side effects and higher efficiency
    • 5.1.3.2. Ongoing research and development activities to introduce effective drugs
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent regulatory policies and lengthy approval process
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type: Rising demand of non-invasive therapies across acral lentiginous melanoma and lentigo maligna melanoma
  • 5.2.2. Product: Boost in demand for next generation drugs to treat disease progression and genetic mutations in Melanoma
  • 5.2.3. Distribution Channel: Rising demand of online channel due to convenience and telehealth support
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Melanoma Drug Market, by Type

• 6.1. Introduction
• 6.2. Acral Lentiginous Melanoma
• 6.3. Lentigo Maligna Melanoma
• 6.4. Nodular Melanoma
• 6.5. Superficial Spreading Melanoma

7. Melanoma Drug Market, by Product

• 7.1. Introduction
• 7.2. Adjuvant Therapy
• 7.3. Biochemotherapy
• 7.4. Chemotherapy Drugs
  • 7.4.1. Dacarbazine (DTIC-Dome)
  • 7.4.2. Temozolomide (Temodar)
• 7.5. Immunotherapy Drugs
  • 7.5.1. Checkpoint Inhibitors
  • 7.5.2. CTLA-4 Inhibitors
• 7.6. Oncolytic Virus Therapy
• 7.7. Targeted Therapy Drugs
  • 7.7.1. BRAF Inhibitors
  • 7.7.2. MEK Inhibitors

8. Melanoma Drug Market, by Distribution Channel

• 8.1. Introduction
• 8.2. Offline
  • 8.2.1. Hospital Pharmacies
  • 8.2.2. Retail Pharmacies
• 8.3. Online

9. Americas Melanoma Drug Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Melanoma Drug Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Melanoma Drug Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. Moderna And Merck Announce mRNA-4157 (V940) In Combination with Keytruda(R) (Pembrolizumab) Demonstrated Continued Improvement in Recurrence-Free Survival and Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection Versus Keytruda at Three Years
  • 12.3.2. Sun Pharma and Philogen's Melanoma Drug Shows Promising Outcome in Phase 3 Trial
  • 12.3.3. U.S. Food and Drug Administration Approves Opdivo (nivolumab) as Adjuvant Treatment for Eligible Patients with Completely Resected Stage IIB or Stage IIC Melanoma
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AB Science
• 2. AbbVie Inc.
• 3. Amgen Inc.
• 4. AstraZeneca PLC
• 5. Bristol-Myers Squibb Company
• 6. CK Life Sciences Int'l., (Holdings) Inc.
• 7. Clinigen Group PLC
• 8. Eli Lilly and Company
• 9. Enzon Pharmaceuticals, Inc.
• 10. F. Hoffmann-La Roche Ltd.
• 11. Genentech, Inc.
• 12. GlaxoSmithKline PLC
• 13. Hikma Pharmaceuticals PLC
• 14. Immunocore Limited
• 15. Merck KGaA
• 16. Moderna, Inc
• 17. Novartis AG
• 18. Pfizer, Inc.
• 19. Philogen S.p.A.
• 20. Regeneron Pharmaceuticals Inc.
• 21. Sun Pharmaceutical Industries Limited
• 22. Taj Pharmaceuticals Limited
• 23. Takeda Pharmaceutical Company Limited
• 24. Wellona Pharma